NCT03854474 2026-03-18Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaNational Cancer Institute (NCI)Phase 1/2 Active not recruiting30 enrolled